Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis

Pharmacotherapy

Volumn 26, Issue 1, 2006, Pages 104-114

  Divittorio, Gino ^a   Jackson, Kirk L ^b   Chindalore, Vishala L ^c   Welker, Weston ^d   Walker, J Bryan ^e  

^a Rheumatology Center of Mobile   (United States)

^b Decatur Internal Medical Center   (United States)

^c Anniston Medical Clinic   (United States)

^d Southside Family Practice of Huntsville   (United States)

^e PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

BMD; Bone mineral density; Bone quality; Fracture; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCITONIN; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D;

BONE DENSITY; BONE DISEASE; BONE MINERALIZATION; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; FRACTURE; HUMAN; META ANALYSIS; NON INVASIVE PROCEDURE; OSTEOPOROSIS; PREDICTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; VERTEBRA FRACTURE; WORLD HEALTH ORGANIZATION;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT; SPINAL FRACTURES;

EID: 30544444212     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2006.26.1.104     Document Type: Review

References (51)

1. U.S. Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general. 2004. Available from http://www.surgeongeneral.gov/library/bonehealth/content.html. Accessed June 22, 2005.
2. Delmas PD. Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis. Bone 2002;30:14-17.
3. Riggs BL, Melton LJ III. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002;17:11-14.
4. Turner CH. Yield behavior of cancellous bone. J Biomech Eng 1989;111:1-5.
5. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000;109:267-76.
6. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 1999;282:637-45.
7. [Erratum in JAMA 1999;282:2124.]
8. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: fracture intervention trial research group. Lancet 1996;348:1535-41.
9. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998;280:2077-82.
10. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA 1999;282:1344-52.
11. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 2000;11:83-91.
12. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
13. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 2000;15:183-7.
14. Delmas PD. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 2000;27:1-3.
15. World Health Organization Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series 843. Geneva: World Health Organization; 1994.
16. Hudson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists 2001 medical guidelines for the prevention and management of postmenopausal osteoporosis. Endocr Pract 2001;7:293-312.
17. National Osteoporosis Foundation. Osteoporosis: physician's guide to prevention and treatment of osteoporosis. Belle Meade, NJ: Excerpta Medica; 1999.
18. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-6.
19. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10.
20. Li Z, Chines AA, Meredith MP. Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture? J Musculoskelet Neuronal Interact 2004;4:64-74.
21. Chesnut CH III, Rosen CJ. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 2001;16:2163-72.
22. Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 2000;11:727-38.
23. Weinstein RS. True strength. J Bone Miner Res 2000;15:621-5.
24. Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture intervention trial research group. Arthritis Rheum 1999;42:1246-54.
25. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9.
26. Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate. The fracture intervention trial. Osteoporos Int 2005;16:842-8.
27. Li Z, Meredith MP, Hoseyni S. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 2001;20:3175-88.
28. Watts N, Bookman R, Smith C, Eastell R, Pack S, Lindsay R. BMD change explains only a fraction of the observed fracture risk reduction in risedronate-treated patients [abstr 546]. Osteoporos Int 2000;11(suppl 2):S203.
29. Watts NB, Johnson TD, Li Z, Kasibhatla C. LS BMD increase accounts for only a fraction of the vertebral fracture reduction at 1 year: results from the VERT and HIP trials of risedronate. Poster presentation at the 30th European symposium on calcified tissues, Rome, Italy, May 8-12, 2003.
30. Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate. J Clin Densitom 2004;7:255-61.
31. Felsenberg D, Watts N, Johnson TD, Li Z, Eastell R. BMD increases explain only a small proportion of non-vertebral fracture risk reduction. Poster presentation at the 30th European symposium on calcified tissues, Rome, Italy, May 8-12, 2003.
32. Guyatt GH, Cranney A, Griffith L, et al. Summary of metaanalyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am 2002;31:659-79.
33. Hochberg MD, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-92.
34. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004;34:599-604.
35. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analysis. J Bone Miner Res 2004;19:330-7.
36. McClung MR, Geusens P, Miller PD, et al, for the Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
37. Bonnick SL. Current controversies in bone densitometry. Curr Opin Rheumatol 2002;14:416-20.
38. Dempster DW. The impact of bone turnover and bone-active agents on bone quality: focus on the hip. Osteoporos Int 2002;13:349-52.
39. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000;11(suppl 6):S2-17.
40. Riggs BL. Are biochemical markers for bone turnover clinically useful for monitoring therapy in individual osteoporotic patients? Bone 2000;26:551-2.
41. Riggs BL, Melton LJ III, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass bone determine antifracture efficacy. Bone 1996;18(suppl 3):S197-201.
42. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Chistiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001;12:922-30.
43. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19:1250-8.
44. Eastell R. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2002;18:1051-6.
45. Boonen S, Haentjens P, Vandenput L, Vanderschueren D. Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes. J Intern Med 2004;255:1-12.
46. Dempster DW, Cosman F, Kurland E, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53.
47. Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 2003;73:423-32.
48. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 1999;42:2309-18.
49. Reid DM, Hughes RA, Laan R, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2001;15:1006-13.
50. Looker AC, Bauer DC, Chesnut CH III, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 200;11:467-80.
51. Cefalu CA. Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin 2004;20:341-9.